Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib

Neoplasms, Gastrointestinal Tract Clinical Trial

Official title:
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer

Status Completed

Clinical Trial Summary

The study will determine if changes in expression of markers involved in the 5-FU pathways are associated with response to treatment with the combination of lapatinib and capecitabine independent of tumor erbB2 status.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00526669
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 2
Start date	March 2008
Completion date	January 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00725712` - Study of GSK1363089 in Metastatic Gastric Cancer	Phase 2
Active, not recruiting	`NCT00680901` - LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib	Phase 3
Completed	`NCT00486954` - Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer	Phase 3